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ABSTRACT
This clinical case presents a patient with a raised and ulcerative lesion with erythematous 
edges in the mouth, on the lower lip that was unsuccessfully treated as herpes labialis. 
Clinical data and laboratory tests (Montenegro skin test, indirect immunofluorescence, direct 
parasite search and polymerase chain reaction) led to the diagnosis of American tegumentary 
leishmaniasis caused by Leishmania (Viannia) sp. Treatment with pentavalent antimonial 
(Glucantime®) for 120 days was not effective and administration of amphotericin B for 
30 days resulted in wound healing. Glucantime® treatment protocol was longer than the 
recommended by the Brazilian Ministry of Health in the handbook of mucosal leishmaniasis. 
This suggests that amphotericin B should have been administered earlier, preventing the 
psychological and social problems faced by the patient. This study reports a rare clinical 
case of primary mucosal leishmaniasis on the lip that had a delayed diagnosis, highlighting 
the precariousness in the management of disease and showing that, despite the importance 
of leishmaniasis in Brazil, it is still neglected by health professionals.
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INTRODUCTION
Leishmaniasis is a parasitic disease caused by protozoa of the genus Leishmania 
sp., transmitted by the bite of naturally infected sandflies of the genus Lutzomyia. 
American tegumentary leishmaniasis (ATL) is the most common form of disease 
and it is manifested as cutaneous and mucosal leishmaniasis. These lead to serious 
clinical manifestations, being the mucosal form the worse one because it affects sites 
such as nose and mouth, leading to permanent scars, disfigurements and, in some 
cases, debilitations with strong psychological involvement1. This form is usually 
secondary to the cutaneous one when it is not correctly treated or is lef untreated, 
but, in rare cases, it can be primary2. In comparison with other mucosal sites, the 
mouth has a shorter evolution time3.
Leishmaniasis is endemic in 98 countries with more than 350 million people 
exposed to the risk and an estimated incidence of one and a half million new cases 
per year of cutaneous leishmaniasis. ATL is a major public health problem in the 
New World and it is a challenge for leishmaniasis endemic countries4.
Leishmaniasis treatment shows several limitations due to problems related 
to serious side effects caused by first-choice drugs, pentavalent antimonial 
(Glucantime®), high toxicity of the second-choice drugs (amphotericin B), in 
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addition, there are still therapeutic failure, emergence 
of resistant parasite strains, daily parenteral treatment, 
high number of patients that discontinue treatment and 
insufficient amount of drugs in endemic areas1. Differences 
between treatment of cutaneous and mucosal forms are 
basically the time and drug concentration, being longer and 
higher in the latter2. Clinical and laboratory monitoring of 
patients, including electrocardiogram, is recommended at a 
minimum interval of 10 days during treatment and 30 days 
after treatment. Laboratory monitoring should include 
serum levels of urea, creatinine, glucose, electrolytes, 
hepatic and pancreatic enzymes5,6.
The aim of this study was to report a rare clinical case of 
primary mucosal leishmaniasis on the lip that had a delayed 
diagnosis, highlighting the precariousness in the disease 
management. In this case, there was also a therapeutic 
failure in the first choice of treatment, which is common, 
but still important.
CASE REPORT
A twenty-five-year-old male patient from Paiçandu, 
Paraná, sought the health care unit of his city because of 
an ulcer on the lower lip that was treated as herpes labialis 
without wound healing or improvement. In August 2015, 
after thirty days of the ulcer appearance, the patient was 
referred to the LEPAC (Laboratório de Ensino e Pesquisa 
em Análises Clínicas) at the Universidade Estadual de 
Maringá. During examination of the lower lip, an ulcerated 
lesion was observed, it was erythematous with raised edges 
and there was the presence of granulomatous, purulent and 
crusty contents characteristic of mucosal leishmaniasis 
(Figure 1A). In a patient interview, he described that he 
frequently fished in the Ivaí river, an endemic region 
for Leishmania (Viannia) sp. and several acquaintances 
acquired leishmaniasis in the same place2.
The conducted laboratory tests were Montenegro 
skin test, direct parasite search in the scraping from 
lesion edges and in the patient’s blood sample an 
indirect immunofluorescence for anti-Leishmania IgG 
antibodies was performed. The Montenegro skin test was 
reactive with an induration of 6 mm in diameter, indirect 
immunofluorescence was positive for anti-Leishmania IgG 
antibodies with titer of 1:80 and the direct parasite search 
was also positive (Figure 1B). Detection of the parasite in 
the scraping from lesion edges and in the patient’s blood 
sample were made by polymerase chain reaction (PCR) 
using primers to amplify a 70-bp fragment of the kinetoplast 
minicircle DNA (kDNA) from parasites belonging to 
Leishmania (Viannia) sp. subgenera. Only the scraping 
material was positive (Figure 1C).
The initial therapeutic regimen for treating leishmaniasis 
was Glucantime®, three ampoules per day (1.215 mg) with 
four cycles of treatment: 20 and 30 days with an interval of 
12 weeks, and two extra-cycles of 40 and 30 days with a 
break of approximately 10 days. This therapeutic scheme 
Figure 1 – Patient’s clinical history: A) Lesion on the lower lip at the time of leishmaniasis diagnosis (one-month-old); B) Direct search 
of parasite in the material obtained by scraping of the lesion, stained by Giemsa; C) Polymerase chain reaction (PCR) showing 
the 70-bp fragment of the kinetoplast minicircle DNA (kDNA) from subgenera Leishmania (Viannia) sp.; lane 1: the patient’s lesion 
sample; lane 2: positive control [DNA from blood sample containing 5x10-3 promastigotes of Leishmania (Viannia) braziliensis]; 
lane 3: the patient’s blood sample; lane 4: negative control (sterile water); lane 5: positive control [DNA from promastigotes of 
Leishmania (Viannia) braziliensis]; lane 6: molecular weight marker 25-bp ladder; D) Patient after treatment with amphotericin B 
(19 months after correct diagnosis)
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used by the patient is actually the one recommended 
to cutaneous leishmaniasis, since, according to what is 
suggested by the Brazilian Ministry of Health, the duration 
of the first cycle is 20 days with 10-20 mg/kg/day of 
Glucantime®, respecting the limit of three ampoules per 
day, being repeated for more 30 days in case of failure 
with an interval of 12 weeks2. At this stage, the patient was 
followed up by a new medical team, who decided not to 
use the therapeutic regimen recommended by the Ministry 
of Health, prescribing other two cycles of Glucantime®, 
40 and 30 days with an interval of approximately 10 
days between them. The treatment with Glucantime® was 
unsuccessful, because the lesion reappeared with nodular 
aspect followed by ulceration. The side effects reported by 
the patient were present only on the first day of Glucantime® 
administration (seasickness and fever). Electrocardiogram 
was used to monitor the treatment side effects. In this 
situation, amphotericin B administration was necessary and 
1 mg/kg/day was administered during 30 days with 
an interval of three days every 10 days, respecting the 
maximum of 50 mg (one flask) per administration. 
Delayed diagnosis and treatment failure led the patient 
to episodes of depression. In March 2017, three months 
after treatment with amphotericin B and 19 months after 
correct diagnosis, the patient was in remission and under 
observation (Figure 1D). The project received the approval 
of the Project Management System (process Nº 1505/1997) 
of the Universidade Estadual de Maringá and the patient 
signed an informed consent form and a photograph consent 
form.
DISCUSSION
This report describes an atypical case of ATL due to 
the clinical presentation (primary mucosal form) on the 
lower lip. The ulcer was treated as herpes labialis and, for 
appropriate treatment, an accurate diagnosis is necessary 
involving anamnesis, lesion characteristics, laboratory tests 
and epidemiological data of the region1.
According to Gomes et al.7, the multidisciplinary 
approach for differentiation among several diagnostic 
possibilities is incredibly important to plan and end therapy, 
avoiding lesion disfigurements. In this case report, there 
was a delay, and failure in the diagnosis leading to lesion 
worsening, evidencing the negligence of the disease by 
health professionals. The Brazilian Ministry of Health 
suggests in the ATL handbook, a primary treatment for 
mucosal form with Glucantime® 20 mg/kg/day for 30 days, 
repeated after 12 weeks, if not efficient for more 30 days, 
totaling 60 days of therapy2. If the symptoms remain, the 
second-choice drug must be used1,2.
This disagreement in the treatment schedule could 
have been caused by the lesion site, which was in the 
transition of the cutaneous (lower base of the lip) and 
the mucosal (lip) tissue. Another important point in the 
treatment was the interval among treatment cycles, which 
was shorter than recommended, based on the fact that 
Glucantime® is a deposit drug with therapeutic effects 
even after treatment6. The change of the medical team that 
was following up the patient shows a still deficient facet of 
health services in the region. The two extra-cycles to which 
the patient was submitted resulted in therapeutic failure, 
probable resistance of the parasite strain and a delay of 
amphotericin B administration. After amphotericin B 
administration, there was a complete wound healing and 
the patient continued to be monitored because clinical 
cure is established after one year after remission. The 
long time elapsed since the lesion appearance, correct 
diagnosis and wound healing (19 months), associated with 
the ulcer site and the need of outpatient care in primary 
health care or hospital facilities for the administration of 
Glucantime® and amphotericin B, respectively, led the 
patient to depression episodes with reflex in his social 
and professional life.
According to Satilho et al.8, ATL is a disease with 
serious clinical manifestations that impacts the patient’s 
appearance, resulting in prejudice and consequently social 
exclusion, affecting the patient’s psychology in the social 
and economic field. Another important point is the need 
for pharmacological monitoring with several laboratory 
tests, not just the electrocardiogram as it was performed 
in the follow-up of this patient. These tests are extremely 
important for monitoring side effects and preventing 
toxicity of drugs used in leishmaniasis treatment, keeping 
the patient’s welfare. In front of this case report, it is clear 
that the long time elapsed between the lesion appearance 
and its healing affects the patient outcomes showing that, 
despite the importance of leishmaniasis in Brazil, it is still 
neglected by health professionals.
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